Adalimumab therapy controlled inflammation and was associated with a lower rate of treatment failure than placebo among children and adolescents with active juvenile idiopathic arthritis (JIA)-associated uveitis, who were taking a stable dose of methotrexate.
That is according to findings of a landmark clinical trial undertaken among 90 patients with JIA-associated uveitis, details of which are published in the New England Journal of Medicine .
The majority (75 per cent) of those treated with adalimumab experienced a significant reduction in eye inflammation. Patients who received adalimumab however also had a much higher incidence of adverse events and serious adverse events than those who received placebo.
Stephen Simpson, director of research and programmes at Arthritis Research UK, said the trial heralds huge promise for transforming the quality of life for the large numbers of children with JIA-associated uveitis. “This trial is an impressive example of how investing in exceptional science can ultimately help change how treatment is delivered with direct and immediate benefit for patients,” he said.
The trial outcomes directly led to changes in commissioning guidelines in the UK.